TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Most patients with colorectal cancer die as a result of the disease spreading to other organs. However, no prevalent mutations have been associated with metastatic colorectal cancers. Instead, particular features of the tumour microenvironment, such as lack of T-cell infiltration, low type 1 T-helper cell (T H 1) activity and reduced immune cytotoxicity or increased TGFβ levels predict adverse outcomes in patients with colorectal cancer. Here we analyse the interplay between genetic alterations and the tumour microenvironment by crossing mice bearing conditional alleles of four main colorectal cancer mutations in intestinal stem cells. Quadruple-mutant mice developed metastatic intestinal tumours that display key hallmarks of human microsatellite-stable colorectal cancers, including low mutational burden, T-cell exclusion and TGFβ-activated stroma. Inhibition of the PD-1-PD-L1 immune checkpoint provoked a limited response in this model system. By contrast, inhibition of TGFβ unleashed a potent and enduring cytotoxic T-cell response against tumour cells that prevented metastasis. In mice with progressive liver metastatic disease, blockade of TGFβ signalling rendered tumours susceptible to anti-PD-1-PD-L1 therapy. Our data show that increased TGFβ in the tumour microenvironment represents a primary mechanism of immune evasion that promotes T-cell exclusion and blocks acquisition of the T H 1-effector phenotype. Immunotherapies directed against TGFβ signalling may therefore have broad applications in treating patients with advanced colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Blockade of the TGFβ signaling pathway promotes enough T cell infiltration to make tumors sensitive to PD-1 therapy [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“Cell analysis of human and mouse CRC specimens showed that CAF is a major contributor to TGF-β production [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“It has been demonstrated in a variety of tumor models, including CRC models, that activation of CAF may induce PD-1 and CTLA-4 expression on relevant immune cells, which leads to tumor insensitivity to immunotherapy or recurrence [39,304,305,306].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“A landmark study from 2018 demonstrated that TGF-β contributes to immune exclusion in colorectal liver metastasis and that inhibition of the TGF-β receptor 1 using the drug galunisertib enhanced tumorous infiltration with T cells, inhibited outgrowth of liver metastases and synergised with anti-PD-L1 therapy to eradicate established lesions.161”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [161]
In the citing paper
“leading to the proposition that combined TGFβ targeting and immune checkpoint blockade may represent an attractive therapeutic strategy for CMS4 colorectal cancer (34).”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [34]
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
lmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Data Analysis Using Regression and Multilevel/Hierarchical Models
Gelman, A., & Hill, J. (2006) · doi:10.1017/cbo9780511790942 · Cited by 13,597
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cited by
Items 701–800 of 1,002
Li, X., Yang, Y., Huang, Q., Deng, Y., Guo, F., Wang, G., & Liu, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.738373 · Cited by 39
Jin, X., Zhang, S., Wang, N., Guan, L., Shao, C., Lin, Y., Liu, J., & Li, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.861601 · Cited by 43
Gui, C., Li, J.-Y., Fu, L., Luo, C., Zhang, C., Tang, Y., Zhang, L., Shu, G., Wu, R., & Luo, J. (2022) · Journal Of Big Data · doi:10.1186/s40537-022-00641-z · Cited by 48
Wang, J., Ding, K., Wang, Y., Yan, T., Xu, Y., Deng, Z., Lin, W., Zhang, L., Zhu, W., Zhao, R., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/4061713 · Cited by 36
“CRC is prone to distant metastases to other organs, and liver metastasis is the main cause of colon cancer-related death [3].”
Fibroblasts in Orchestrating Colorectal Tumorigenesis and Progression
Abudukelimu, S., de Miranda, N. F. C. C., & Hawinkels, L. J. A. C. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.01.013 · Cited by 36
Miao, Z., Liu, S., Xiao, X., & Li, D. (2020) · Gene · doi:10.1016/j.gene.2020.144604 · Cited by 37
Contribution of Macrophages and T Cells in Skeletal Metastasis
Mendoza‐Reinoso, V., McCauley, L. K., & Fournier, P. G. J. (2020) · Cancers · doi:10.3390/cancers12041014 · Cited by 37
Huang, M., Ji, Y., Yan, J., Qi, T., Zhang, S., Li, T., Lü, S., Liu, Y., & Liu, M. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.110697 · Cited by 33
PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer
Shen, Y., Teng, Y., Lv, Y.-P., Zhao, Y., Qiu, Y., Chen, W., Wang, L., Wang, Y., Mao, F., Cheng, P., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000422 · Cited by 35
Effects of Bacillus subtilis iturin A on HepG2 cells in vitro and vivo
Zhao, H., Yan, L., Guo, L., Sun, H., Huang, Q., Shao, D., Jiang, C., & Shi, J. (2021) · AMB Express · doi:10.1186/s13568-021-01226-4 · Cited by 35
“2018), and affect the antigen presenting function of dendritic cells, thus leading to the immune escape of tumor cells (Tauriello et al. 2018).”
BackgroundCao, R., Ma, B., Wang, G., Xiong, Y., Tian, Y., & Yuan, L. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.06.011 · Cited by 39
“Previous studies demonstrated that TGF-b/EMT signaling activation could result in decreased priming of effector T cells into tumor parenchyma as well as hamper their cytotoxicity effects.(47) Additionally, we found that the ICI immunotherapy responders have a lower HPXscore, and patients with a lower HPXscore were mor…”
BackgroundSon, S., Shin, J. M., Shin, S., Kim, C. H., Lee, J. A., Ko, H., Lee, E. S., Jung, J. M., Kim, J., & Park, J. H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121058 · Cited by 34
The overall process of metastasis: From initiation to a new tumor
Fan, T., Kuang, G., Long, R., Han, Y., & Wang, J. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188750 · Cited by 36
Li, A., Chang, Y., Song, N., Wu, X., Chung, D., Riesenberg, B., Velegraki, M., Giuliani, G. D., Das, K., Okimoto, T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005433 · Cited by 35
The new progress in cancer immunotherapy
Shimu, A. S., Wei, H.-X., Li, Q., Zheng, X., & Li, B. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00887-0 · Cited by 42
“Two studies have recently reported that combining PD-1/ PD-L1 therapies with the cytokine TGF-β can enhance the efficacy of anti-tumor response through CTL infiltration to prevent the growth and metastatic spread of both murine EMT6 breast mammary carcinoma and orthotopic colorectal cancer vaccination models [22, 46].”
BackgroundLiang, Z., Xie, H., Shen, W., Le, S., Zeng, L., Huang, X., Zhu, Q., Zhai, X., Li, K., Qiu, Z., et al. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2709263 · Cited by 36
Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer
Zhang, H., Ye, L., Yu, X., Jin, K., & Wu, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956984 · Cited by 39
“Hypoxia promotes CAF recruitment, connective tissue hyperplasia and activation (77), and transforming growth factor-b expression in CAFs, resulting in the exclusion of CD8 T cells from the tumor parenchyma to hinder antitumor immunity following immunotherapy (78, 79).”
BackgroundImmunotherapeutic progress and application of bispecific antibody in cancer
Kang, J., Sun, T., & Zhang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020003 · Cited by 42
Advances in immunotherapy for MMR proficient colorectal cancer
Lote, H., Starling, N., Pihlak, R., & Gerlinger, M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102480 · Cited by 38
Hanley, C. J., & Thomas, G. J. (2021) · Oncotarget · doi:10.18632/oncotarget.27936 · Cited by 35
“com treatment was effective in curing established metastases [37].”
BackgroundDark force rising: Reawakening and targeting of fetal-like stem cells in colorectal cancer
Fey, S. K., Vaquero-Siguero, N., & Jackstadt, R. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114270 · Cited by 32
Wang, Q., Shen, X., Chen, G., & Du, J. (2023) · International Journal of Cancer · doi:10.1002/ijc.34464 · Cited by 38
“For example, CAFs are major contributors to TGF-β, and activation of TGF-β in the TME can have profound immunosuppressive activity.(44) CAFs can also affect T-cell trafficking.”
BackgroundCancer‐associated fibroblasts: Is it a key to an intricate lock of tumorigenesis?
Aden, D., Zaheer, S., Ahluwalia, H., & Ranga, S. (2023) · Cell Biology International · doi:10.1002/cbin.12004 · Cited by 33
“Alternative approaches to inhibit CAF (specifically myCAF) activation include TGF‐β blockade (Grauel et al., 2020; Mariathasan et al., 2018; Tauriello et al., 2018).”
BackgroundZheng, H., Wang, G., Liu, M., & Cheng, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1168226 · Cited by 39
Tang, S., Wang, Y., Luo, R., Fang, R., Liu, Y., Hang, X., Ran, P., Tong, Y., Sun, M., Tan, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45306-y · Cited by 45
RetractedZhu, C., Teng, L., Lai, Y., Yao, X., Fang, Y., Wang, Z., Lin, S., Zhang, H., Li, Q., Li, Y., et al. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05215-1 · Cited by 35
Ho, H., Chou, T., Yang, S.-H., Jiang, J., Chen, W.-S., Chao, Y., & Teng, H. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02942-y · Cited by 33
Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer
Vafaizadeh, V., & Barekati, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00162 · Cited by 36
“…studies revealed that combinational therapy of Frontiers in Cell and Developmental Biology | www.frontiersin.org 5 March 2020 | Volume 8 | Article 162 both TGFβ and PD-L1 resulted in synergistic anti-tumor effect in both breast and colorectal cancers (Knudson et al., 2018; Tauriello et al., 2018).”
BackgroundWestergaard, M. C. W., Milne, K., Pedersen, M., Hasselager, T., Olsen, L. R., Anglesio, M. S., Borch, T. H., Kennedy, M., Briggs, G., Ledoux, S., et al. (2020) · Cancers · doi:10.3390/cancers12123828 · Cited by 35
Kasashima, H., Durán, Á., Cid-Diaz, T., Muta, Y., Kinoshita, H., Batlle, E., Díaz-Meco, M. T., & Moscat, J. (2021) · STAR Protocols · doi:10.1016/j.xpro.2021.100297 · Cited by 32
Self-citationAdvances in Modeling the Immune Microenvironment of Colorectal Cancer
Yoon, P., Piccolo, N. D., Shirure, V. S., Peng, Y., Kirane, A., Canter, R. J., Fields, R. C., George, S. C., & Gholami, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.614300 · Cited by 35
Foroutan, M., Molania, R., Pfefferle, A., Behrenbruch, C., Scheer, S., Kallies, A., Speed, T. P., Cursons, J., & Huntington, N. D. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0137 · Cited by 37
“response after blockade of TGF-β signalling, driven by increasing T cell infiltration of the tumours and promotion of a TH1 phenotype [37].”
BackgroundAntimetastatic defense by CD8+ T cells
de Lara, P. T., Castañón, H., Sterpi, M., & van den Broek, M. F. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.006 · Cited by 33
Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity
Anderson, T. S., McCormick, A. L., Piersall, S. L., Okpalanwaka, I. F., & Lowe, D. B. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.009 · Cited by 37
TGF-β promotes stem-like T cells via enforcing their lymphoid tissue retention
Ma, C., Wang, L., Liao, W., Liu, Y., Mishra, S., Li, G., Zhang, X., Qiu, Y., Lu, Q., & Zhang, N. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20211538 · Cited by 34
Shinkawa, T., Ohuchida, K., & Nakamura, M. (2022) · Cancers · doi:10.3390/cancers14163994 · Cited by 36
Transforming growth factor‐β signalling in tumour resistance to the anti‐PD ‐(L)1 therapy: Updated
Mortezaee, K., & Majidpoor, J. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17666 · Cited by 35
Tomlins, S. A., Khazanov, N. A., Bulen, B. J., Hovelson, D. H., Shreve, M. J., Lamb, L. E., Matrana, M. R., Burkard, M. E., Yang, E. S.-H., Edenfield, W. J., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00243-7 · Cited by 32
Liu, Y., Ma, J., Wang, X., Liu, P., Cai, C., Han, Y., Zeng, S., Feng, Z., & Shen, H. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106862 · Cited by 35
Ahuja, S., & Zaheer, S. (2023) · Cell Biology International · doi:10.1002/cbin.12097 · Cited by 37
“Several researchers have tested a combination of TGF ‐ β inhibitors with anti ‐ PD ‐ 1/PD ‐ L1 antibodies, results show that combined drug treatment gave better results with greater antitumor activity in human cell lines and murine models of several tumors (Dodagatta ‐ Marri et al., 2019; Lan et al., 2018; Mariathasan…”
BackgroundResultInfluentialKim, S. Y., & Kim, T. W. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000634 · Cited by 35
Hachey, S. J., Sobrino, A., Lee, J. G., Jafari, M. D., Klempner, S. J., Puttock, E. J., Edwards, R. A., Lowengrub, J. S., Waterman, M. L., Zell, J. A., et al. (2022) · Translational research · doi:10.1016/j.trsl.2022.11.011 · Cited by 35
Singh, S. P., Gouri, V., & Samant, M. (2023) · Medical Oncology · doi:10.1007/s12032-023-02204-5 · Cited by 37
“Further investigation revealed that TGF-β could induce immuno-suppression by promoting the formation of tumors with the T cell-exclusion phenotype that was predisposed to be resistant to ICI treatment [133].”
BackgroundYe, Y., Jiao, H., Wang, S., Xiao, Z., Zhang, D., Qiu, J., Zhang, L., Zhao, Y., Li, T., Li-Liang, et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0958-1 · Cited by 31
Velaparthi, U., Darne, C. P., Warrier, J., Liu, P., Rahaman, H., Augustine‐Rauch, K. A., Parrish, K. E., Yang, Z., Swanson, J., Brown, J. G., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00552 · Cited by 35
Combinatorial Immunotherapies for Metastatic Colorectal Cancer
Janssen, E., Subtil, B., Ortiz, F. D. L. J., Verheul, H. M. W., & Tauriello, D. V. F. (2020) · Cancers · doi:10.3390/cancers12071875 · Cited by 34
Self-citationMoradpoor, R., Gharebaghian, A., Shahi, F., Mousavi, A., Salari, S., Akbari, M. E., Ajdari, S., & Salimi, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01101 · Cited by 36
Wu, B., Tao, L., Yang, D., Li, W., Xu, H., & He, Q. (2020) · BioMed Research International · doi:10.1155/2020/2719739 · Cited by 33
Therapeutic Implications of TGFβ in Cancer Treatment: A Systematic Review
Gómez‐Gil, V. (2021) · Cancers · doi:10.3390/cancers13030379 · Cited by 30
“A higher number of active T cells will provide a greater response that will kill cancer cells more efficiently and will reduce the growth of metastatic tumors [148,149].”
BackgroundKeshinro, A. O., Vanderbilt, C., Kim, J. K., Fırat, C., Chen, C., Yaeger, R. D., Ganesh, K., Segal, N. H., Gönen, M., Shia, J., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00456 · Cited by 39
“Age, mean (range), years 58 (26-90) 66 (25-92) 47 (24-82) , .”
TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model
Siewe, N., & Friedman, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252620 · Cited by 34
“[19] identified TGF-β signaling in tumor microenvironment as a determinant of tumor T cell role in affecting poor response to PD-1/PD-L1 blockade.”
BackgroundRing, S. S., Cupovic, J., Onder, L., Lütge, M., Perez‐Shibayama, C., Gil‐Cruz, C., Scandella, E., Martin, A. D., Mörbe, U., Hartmann, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25057-w · Cited by 36
Genome-Editing-Mediated Restructuring of Tumor Immune Microenvironment for Prevention of Metastasis
Kim, D.-Y., Wu, Y., Shim, G., & Oh, Y. (2021) · ACS Nano · doi:10.1021/acsnano.1c05420 · Cited by 32
The histone demethylase PHF8 regulates TGFβ signaling and promotes melanoma metastasis
Moubarak, R. S., de Pablos-Aragoneses, A., Ortiz-Barahona, V., Gong, Y., Gowen, M. F., Dolgalev, I., Shadaloey, S. A. A., Argibay, D., Karz, A., Itter, R. V., et al. (2022) · Science Advances · doi:10.1126/sciadv.abi7127 · Cited by 30
“Moreover, recent studies elegantly demonstrated that high TGF signaling in metastatic tumor margins contributes to reduced immune surveillance and poor therapy response in metastatic colorectal (53) and urothelial (54) cancers.”
BackgroundA pan-cancer analysis of molecular characteristics and oncogenic role of gasdermins
Mu, M., Yu, Q., Zhang, Q., Guo, J., Wang, X., Sun, X., & Yu, J. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02483-4 · Cited by 33
An Update to Hallmarks of Cancer
Ravi, S., Alencar, A. M., Arakelyan, J., Xu, W., Stauber, R., Wang, C.-C. I., Papyan, R., Ghazaryan, N. A., & Pereira, R. M. (2022) · Cureus · doi:10.7759/cureus.24803 · Cited by 48
“Blocking TGFβ signaling could potentially promote antitumor immunity [171], which is proved in advanced colorectal cancer using TGFβ inhibitors [172].”
BackgroundHarnessing redox signaling to overcome therapeutic-resistant cancer dormancy
Qin, S., Li, B., Ming, H., Nice, E. C., Zou, B., & Huang, C. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188749 · Cited by 32
Angelis, M. L. D., Francescangeli, F., Nicolazzo, C., Xhelili, E., Torre, F. L., Colace, L., Bruselles, A., Macchia, D., Vitale, S., Gazzaniga, P., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.869485 · Cited by 34
“However, pioneer studies have performed orthotopic xenografts with mouse tumor organoids (15, 16), with human spheroids (17, 18) or organoids (19, 20) and with cells directly derived from human colorectal tumors (21–26).”
BackgroundBaba, S. K., Baba, S. K., Mir, R., Elfaki, I., Algehainy, N. A., Ullah, M. F., Barnawi, J., Altemani, F. H., Alanazi, M. A., Mustafa, S. K., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1164301 · Cited by 36
“Accumulated evidence has demonstrated that NOTCH, TGFβ/SMAD, PI3K/AKT, Wnt/β-catenin, JAK/STAT, and MEK/ERK are responsible for inducing the EMT-activating transcription factors (EMT-TFs) expression, particularly SNAIL, TWIST, and ZEB, which simultaneously prevent the epithelial state–related gene expression and enhan…”
BackgroundTurning Cold Tumors Hot by Blocking TGF-β
Ros, X. R., & Vermeulen, L. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.03.005 · Cited by 31
Influence of Innate Immunity on Cancer Cell Stemness
Pastò, A., Consonni, F. M., & Sica, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093352 · Cited by 34
Kment, J. L., Newsted, D., Young, S., Vermeulen, M., Laight, B. J., Greer, P. A., Lan, Y., & Craig, A. W. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02677-9 · Cited by 34
Menche, C., Schuhwerk, H., Armstark, I., Gupta, P., Fuchs, K., van Roey, R., Mosa, M. H., Hartebrodt, A., Hajjaj, Y., Ezquerra, A. C., et al. (2024) · EMBO Reports · doi:10.1038/s44319-024-00186-7 · Cited by 35
“…β signaling has been shown essential for the acquisition of classical myo fi broblast phenotypes (Bif fi et al, 2019; Elyada et al, 2019; Sahai et al, 2020; Tauriello et al, 2018; Tauriello et al, 2022) and in tumor cells, ZEB1 is a key mediator of TGF β signaling (Krebs et al, 2017; Schuhwerk et…”
InfluentialTherapeutic targeting of mismatch repair-deficient cancers
Johannet, P. M., Rousseau, B., Aghajanian, C. A., Foote, M. B., & Diaz, L. A. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01054-6 · Cited by 50
“Fibrosis might in and of itself dampen antitumour immune activity, although fibrotic tumours also have higher expression of TGFβ, which can facilitate immune evasion and T cell exhaustion and thus further drive resistance to ICIs 313 . cGAS–STING signalling .”
He, Y., Cong, C., Liu, Z., Li, X., Zhu, R., & Gao, D. (2019) · Chemical Engineering Journal · doi:10.1016/j.cej.2019.122252 · Cited by 30
Bu, H., Shen, F., & Cui, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s220401 · Cited by 31
“TGF-β not only plays a regulatory role in the physiology of the normal colon(6) but is also a key player in CRC development, angiogenesis, progression, metastasis and immune evasion.(7,8) Not surprisingly therefore, the TGF-β/Smad regulatory axis is the target of multiple antiCRC chemotherapeutics.”
BackgroundPharmacogenomics, biomarker network, and allele frequencies in colorectal cancer
López‐Cortés, A., Paz‐y‐Miño, C., Guerrero, S. X., Jaramillo-Koupermann, G., Cáceres, Á. L., Intriago-Baldeón, D. P., García-Cárdenas, J. M., Guevara‐Ramírez, P., Armendáriz‐Castillo, I., Leone, P., et al. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0102-4 · Cited by 32
Xu, W., Yang, Y., Hu, Z., Head, M., Mangold, K. A., Sullivan, M. E., Wang, E., Saha, P., Gulukota, K., Helseth, D. L., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.078 · Cited by 32
Fibroblast Reprogramming in Gastrointestinal Cancer
Melissari, M., Chalkidi, N., Sarris, M. E., & Koliaraki, V. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00630 · Cited by 33
Src Family Tyrosine Kinases in Intestinal Homeostasis, Regeneration and Tumorigenesis
Sirvent, A., Mevizou, R., Naim, D., Lafitte, M., & Roche, S. (2020) · Cancers · doi:10.3390/cancers12082014 · Cited by 35
Liu, C., Zhou, F., Yan, Z., Shen, L., Zhang, X., He, F., Wang, H., Lu, X., Yu, K., Zhao, Y., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15457 · Cited by 32
“TGF-β has been reported to play an important role in cancer development and immunology (Daniele V. F. Tauriello et al., 2018).”
BackgroundInfluentialBFAR coordinates TGFβ signaling to modulate Th9-mediated cancer immunotherapy
Pei, S., Huang, M., Huang, J., Zhu, X., Wang, H., Romano, S., Deng, X., Wang, Y., Luo, Y., Hao, S., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202144 · Cited by 33
Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics
Guerra, E., Pietro, R. D., Basile, M., Trerotola, M., & Alberti, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010405 · Cited by 32
“An immunosuppressive role of CAF-derived TGF-β modulates the functions of T cells, macrophages, and neutrophils, and increased TGF-β favors immune evasion with T-cell exclusion, preventing acquisition of the T helper 1effector phenotype [149].”
BackgroundNeutrophils: Musketeers against immunotherapy
Zahid, K. R., Raza, U., Tumbath, S., Jiang, L., Xu, W., & Huang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.975981 · Cited by 32
van den Bulk, J., van der Ploeg, M., Ijsselsteijn, M. E., Ruano, D., van der Breggen, R., Duhen, R., Peeters, K. C. M. J., Sarasqueta, A. F., Verdegaal, E. M. E., van der Burg, S. H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005887 · Cited by 34
Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents
Zhang, Y., Zhao, Y., Tebben, A. J., Sheriff, S., Ruzanov, M., Fereshteh, M., Fan, Y., Lippy, J., Swanson, J., Ho, C., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00357 · Cited by 32
Pembrolizumab for the treatment of colorectal cancer
Coupez, D., Hulo, P., Touchefeu, Y., Bossard, C., & Bennouna, J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1718095 · Cited by 33
A Single-Cell Tumor Immune Atlas for Precision Oncology
Nieto, P., Elosua-Bayes, M., Trincado, J. L., Marchese, D., Massoni-Badosa, R., Salvany, M., Henriques, A., Mereu, E., Moutinho, C., Ruiz, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.26.354829 · Cited by 30
Self-citationYang, Y., Yang, H. H., Tang, B., Wu, A. M. L., Flanders, K. C., Moshkovich, N., Weinberg, D. S., Welsh, M. A., Weng, J., Ochoa, H. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2370 · Cited by 29
“Recent studies have suggested that anti-TGFb therapy might be particularly effective in tumors with an “immune-excluded” phenotype, because stromally derived TGFb can reduce immune cell infiltration into the tumor (4, 5).”
BackgroundKatagata, M., Okayama, H., Nakajima, S., Saito, K., Sato, T., Sakuma, M., Fukai, S., Endo, E., Sakamoto, W., Saito, M., et al. (2023) · Cancers · doi:10.3390/cancers15204943 · Cited by 32
“To this end, Tauriello et al. used a mouse model of MSS CRC displaying the CMS4 phenotype and TGF β -activated stroma, demonstrating that increased TGF β in the TME represented a primary mechanism of immune evasion and that TGF β inhibitors rendered tumors susceptible to PD-1/PD-L1 blockade [9].”
BackgroundNeoadjuvant immunotherapy in mismatch-repair-proficient colon cancers
Tan, P. B., Verschoor, Y. L., van den Berg, J. G., Balduzzi, S., Kok, N. F. M., Ijsselsteijn, M. E., Moore, K., Jurdi, A. A., Tin, A., Kaptein, P., et al. (2025) · Nature · doi:10.1038/s41586-025-09679-4 · Cited by 42
“On the basis of these results and previous data showing an association between TGFβ and non-response in urothelial and gynaecological malignancies 53,54 , it may be of interest to explore the role of TGFβ in response to ICB in patients with pMMR colon cancer in future trials 46,55–58 .”
Premkumar, K., & Shankar, B. S. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02666-w · Cited by 34
Voluntary wheel running can lead to modulation of immune checkpoint molecule expression
Bay, M. L., Unterrainer, N., Stagaard, R., Pedersen, K. S., Schauer, T., Staffeldt, M. M., Christensen, J. F., Højman, P., Pedersen, B. K., & Gehl, J. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1817550 · Cited by 33
Asiry, S., Kim, G., Filippou, P. S., Sanchez, L. R., Entenberg, D. R., Marks, D. K., Oktay, M. H., & Karagiannis, G. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654877 · Cited by 30
Li, T., Wang, H., Xu, J., Li, C., Zhang, Y., Wang, G., Liu, Y., Cai, S., Fang, W., Li, J., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211038477 · Cited by 36
Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy
Halima, A., Vuong, W., & Chan, T. A.-T. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154945 · Cited by 38
“This phenotype is associated with increased TGF-β signaling in tumor fibroblasts (117).”
BackgroundDiagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
Meliante, P. G., Zoccali, F., VINCENTIIS, M. D., Ralli, M., Petrella, C., Fiore, M., Minni, A., & Barbato, C. (2023) · Diagnostics · doi:10.3390/diagnostics13050862 · Cited by 33
Mouse models in colon cancer, inferences, and implications
Kucherlapati, M. H. (2023) · iScience · doi:10.1016/j.isci.2023.106958 · Cited by 33
Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics
Janin, M., Dávalos, V., & Esteller, M. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10120-3 · Cited by 35
“Using mouse models, it has been shown that a combination of four mutations in genes commonly found in primary human cancers ( Apc fl/fl , Kras LSL−G12D , Tgfbr2 fl/fl , and Trp53 fl/fl ) promotes metastases, but the lack of one of them hinders the metastatic ability [50].”
Yi, M., Li, T., Niu, M., Wu, Y., Zhao, B., Shen, Z., Hu, S., Zhang, C. H., Zhang, X., Zhang, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202408598 · Cited by 40
Ludwig, N., Wieteska, Ł., Hinck, C. S., Yerneni, S. S., Azambuja, J. H., Bauer, R. J., Reichert, T. E., Hinck, A. P., & Whiteside, T. L. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0944 · Cited by 33
“TGFbwas chosen as a target of our therapies because of its ability to modulate the TME and to suppress antitumor immune responses (7).”
BackgroundShi, Y., Kong, Z., Liu, P., Hou, G., Wu, J., Ma, W., Cheng, X., & Wang, Y. (2021) · Cells · doi:10.3390/cells10051142 · Cited by 32
Sato, K., Parag‐Sharma, K., Terajima, M., Musicant, A. M., Murphy, R. M., Ramsey, M. R., Hibi, H., Yamauchi, M., & Amelio, A. L. (2021) · Neoplasia · doi:10.1016/j.neo.2021.05.014 · Cited by 32
The Curcumin Analog GO-Y030 Controls the Generation and Stability of Regulatory T Cells
Maruyama, T., Kobayashi, S., Nakatsukasa, H., Moritoki, Y., Taguchi, D., Sunagawa, Y., Morimoto, T., Asao, A., Jin, W., Owada, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687669 · Cited by 30
“Based on these findings, TGF-b and downstream signaling molecules may serve as novel targets for cancer immunotherapy (14, 50).”
BackgroundTGFβ: Signaling Blockade for Cancer Immunotherapy
Chen, S., Mamaï, O., & Akhurst, R. J. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070620-103554 · Cited by 31
“…within the tumor but also stimulates the migration of T cells from tumor stroma into the parenchyma of immune-excluded tumors, with consequent tumor regression or rejection (Mariathasan et al. 2018, Tauriello et al. 2018, Dodagatta-Marri et al. 2019, Desbois et al. 2020, Gunderson et al. 2020).”
BackgroundOncogenic Pathways in Neurodegenerative Diseases
Varela, L., & García-Rendueles, M. E. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063223 · Cited by 31
Peng, P., Lou, Y., Wang, J., Wang, S., Liu, P., & Xu, L. X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944115 · Cited by 31
Thiery, J. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00103 · Cited by 33
“Similarly, poor response to immunotherapies in the metastatic urothelial, lung, and colon cancer and melanoma have been linked to TGFβ signature in CAFs [145, 146].”
BackgroundWang, S., Fan, G., Li, L., He, Y., Lou, N., Xie, T., Dai, L., Gao, R., Yang, M., Shi, Y., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03428-0 · Cited by 30
“And preclinical studies showed a more potent response in mouse models by co-administration of TGFβ inhibitors and anti-PD1/PD-L1 antibodies [22, 23].”
BackgroundShen, C., Liu, J., Jiao, W., Zhang, X., Zhao, X., Yang, X., & Wang, Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05164-5 · Cited by 31
“Meanwhile, TGF-β signaling blockade has shown great potential in boosting the sensitivity of PD-L1/PD-1 inhibitors (Mariathasan et al. 2018; Tauriello et al. 2018).”
Background
Metadata
- Authors
- Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., Byrom, D., Matarin, J. A., Calon, A., Rivas, E. I., Nebreda, A. R., Riera, A., Attolini, C. S.-O., & Batlle, E.
- Affiliations
- Institute for Research in Biomedicine (ES)
- Universitat Autònoma de Barcelona (ES)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Batlle, Eduard
- ORCID
- Venue
- Nature
- Published
- 2018-02
- Volume
- 554
- Issue
- 7693
- Pages
- 538-543
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2788975052
- Cited by
- 1,851
- References
- 43
- Citations by year
- 2026: 193 · 2025: 186 · 2024: 159 · 2023: 211 · 2022: 280 · 2021: 305 · 2020: 247 · 2019: 176 · 2018: 94
- FWCI
- 77.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TGF-beta signaling, colorectal cancer metastasis, immune evasion, T-cell exclusion, tumor microenvironment, immune checkpoint inhibitors, TGF-beta inhibition, liver metastasis, microsatellite stable colorectal cancer, genetically engineered mouse models, organoid transplantation, combination immunotherapy
- MeSH terms
- Alleles, Animals, Cell Differentiation, Colonic Neoplasms, Disease Models, Animal, Drug Synergism, Female, Humans, Immunotherapy, Intestinal Mucosa, Intestines, Liver Neoplasms, Male, Mutation, Neoplasm Metastasis, Stem Cells, T-Lymphocytes, Cytotoxic, Transforming Growth Factor beta, Th1 Cells, Mice, Immune Evasion, Tumor Microenvironment, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.